PDPN and B-cell chronic lymphocytic leukemia: Platelets from ibrutinib- or acalabrutinib-treated CLL patients do not aggregate in response to the CLEC-2 agonist rhodocytin and cannot adhere to the CLEC-2 ligand podoplanin under venous flow conditions ex vivo (Nicolson et al., 2021).